CTICasesCrizotinib-Induced Thymic Hyperplasia
Imaging findings
Surveillance CT of a patient with ALK-rearranged lung adenocarcinoma treated with crizotinib shows a rapidly developing, well-marginated anterior mediastinal mass containing fat. Over subsequent scans, the mass slowly regressed, consistent with benign thymic rebound hyperplasia.
Key takeaways
Targeted therapies (like crizotinib) can induce benign thymic rebound hyperplasia. This presents as a rapidly growing anterior mediastinal mass that can mimic tumor progression or lymphoma but slowly regresses without intervention.
AI-assisted summary — may contain errors. Verify against the source video. Learn more
More from this webinar
- Atypical Acute myocardial InfarctionVascular
- Tracheobronchial and Parenchymal AmyloidosisMetabolic
- Thymoma with Cardiac MRI TaggingNeoplastic
- Mediastinal and Retroperitoneal Venous MalformationCongenital
- Paradoxical EmbolusVascular
- Wiskott-Aldrich Syndrome BronchiectasisCongenital
- Beta Thalassemia Extramedullary HematopoiesisMetabolic
- Pulmonary Artery SarcomaNeoplastic
See all cases from February 28, 2019 →